CartiHeal Initiates Agili-C Implant IDE Multinational Pivotal Study

CartiHeal enrolled 16 patients in its investigational device exemption study of Agili-C™ implants in the treatment of joint surface lesions.

The study will include a minimum 250 patients in U.S. and ex-U.S. centers in support of a premarket approval submission. Its objective is to demonstrate superiority of Agili-C vs. microfracture and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us